Please login to the form below
Qdenga
This page shows the latest Qdenga news and features for those working in and with pharma, biotech and healthcare.
Takeda’s dengue vaccine receives MHRA approval for those aged four years and older
Takeda’s dengue vaccine, Qdenga (TAK-003), has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) for those aged four years and older, the company announced. ... The MHRA’s decision, which follows the European
Latest news
-
Takeda to acquire Nimbus’ TYK2 inhibitor in deal worth $6bn
Earlier this month, Takeda’s dengue vaccine candidate, Qdenga (TAK-003), was approved by the European Commission for the prevention of dengue disease in individuals aged four years and over. ... The decision, which followed a positive recommendation
-
Takeda’s dengue vaccine receives EC approval
The decision follows a positive recommendation for Qdenga from the CHMP in October. ... announced. The decision makes Qdenga the only dengue vaccine approved in the EU for use in individuals regardless of previous dengue exposure.
-
Takeda’s dengue vaccine candidate recommended for approval by CHMP
Takeda’s dengue vaccine, known as QDENGA, was approved by the Indonesia National Agency for Drug and Food Control, BADAN POM, in August this year for the prevention of dengue disease
More from news
Approximately 2 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- 2023 PM Society Awards – winners announced
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Trust me, I’m from pharma
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- Genmab hires first chief operating officer
- A relentless commitment to neuroscience
PMHub
Dice Medical Communications
Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
